Anti CD38 monoclonal antibodies for multiple myeloma treatment
CD38 is a transmembrane glycoprotein with ectoenzymatic activity and is highly and uniformly expressed on multiple myeloma (MM) cells. CD38 is expressed also at relatively low levels on normal lymphoid and myeloid cells, and in some tissues of non-hematopoietic origin. The specificity of this target...
Saved in:
Main Authors: | Alessandro Gozzetti (Author), Sara Ciofini (Author), Martina Simoncelli (Author), Adele Santoni (Author), Paola Pacelli (Author), Donatella Raspadori (Author), Monica Bocchia (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2022-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Impact of Anti-CD38 Monoclonal Antibody Therapy on CD34+ Hematopoietic Stem Cell Mobilization, Collection, and Engraftment in Multiple Myeloma Patients-A Systematic Review
by: Flavia Bigi, et al.
Published: (2024) -
The Role of Monoclonal Antibodies in Smoldering and Newly Diagnosed Transplant-Eligible Multiple Myeloma
by: Elena Zamagni, et al.
Published: (2020) -
Monoclonal Antibodies: Leading Actors in the Relapsed/Refractory Multiple Myeloma Treatment
by: Sonia Morè, et al.
Published: (2020) -
Monoclonal Antibodies in Smoldering Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance: Current Status and Future Directions
by: Valeria Ferla, et al.
Published: (2024) -
The Role of Monoclonal Antibodies in the Treatment of Myeloma Kidney Disease
by: Daniele Derudas, et al.
Published: (2024)